Anis Hamid

7PUBLICATIONS
67CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Oct 16, 2026
The molecular heterogeneity and clinical impact of genomic driver alterations in prostate cancer.

|Sep 09, 2026
Recurrent mechanisms of biallelic epigenetic inactivation reveal new putative tumour suppressor genes in prostate cancer.

|Nov 03, 2025
Interprovider Variation in Initiation of Bone-Modifying Agents for Patients With Prostate Cancer.

Aaron P Mitchell, Andrew Salner, Paul Palyca

|Apr 15, 2023
A novel prostate cancer subtyping classifier based on luminal and basal phenotypes.

Adam B Weiner, Yang Liu, Alex Hakansson

|Apr 17, 2021
NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants.

Katherine L Morel, Anis A Hamid, John G Clohessy

|Jan 11, 2018
Risk of febrile neutropenia and early treatment cessation in men receiving standard and dose-reduced 3-weekly docetaxel for metastatic castration-resistant prostate cancer.

Anis A Hamid, Kaspar Willson, Andrew D Vincent

Pageof 2

Frequent Collaborators

2 joint publications

Benedikt Brors

2 joint publications

Housheng Hansen He

2 joint publications

Abraham Gihawi

2 joint publications

Géraldine Cancel-Tassin